Cargando…
Gut Microbiota Modulation as a Potential Target for the Treatment of Lung Infections
The gastrointestinal and respiratory systems are colonized by a complex ecosystem of microorganisms called the microbiota. These microorganisms co-evolved over millions of years with the host, creating a symbiotic relationship that is fundamental for promoting host homeostasis by producing bioactive...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453009/ https://www.ncbi.nlm.nih.gov/pubmed/34557097 http://dx.doi.org/10.3389/fphar.2021.724033 |
_version_ | 1784570202973798400 |
---|---|
author | Cruz, Clênio Silva Ricci, Mayra Fernanda Vieira, Angélica Thomaz |
author_facet | Cruz, Clênio Silva Ricci, Mayra Fernanda Vieira, Angélica Thomaz |
author_sort | Cruz, Clênio Silva |
collection | PubMed |
description | The gastrointestinal and respiratory systems are colonized by a complex ecosystem of microorganisms called the microbiota. These microorganisms co-evolved over millions of years with the host, creating a symbiotic relationship that is fundamental for promoting host homeostasis by producing bioactive metabolites and antimicrobial molecules, and regulating the immune and inflammatory responses. Imbalance in the abundance, diversity, and function of the gut microbiota (known as dysbiosis) have been shown to increase host susceptibility to infections in the lungs, suggesting crosstalk between these organs. This crosstalk is now referred to as the gut-lung axis. Hence, the use of probiotics, prebiotics, and synbiotics for modulation of gut microbiota has been studied based on their effectiveness in reducing the duration and severity of respiratory tract infections, mainly owing to their effects on preventing pathogen colonization and modulating the immune system. This review discusses the role and responses of probiotics, prebiotics, and synbiotics in the gut-lung axis in the face of lung infections. |
format | Online Article Text |
id | pubmed-8453009 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84530092021-09-22 Gut Microbiota Modulation as a Potential Target for the Treatment of Lung Infections Cruz, Clênio Silva Ricci, Mayra Fernanda Vieira, Angélica Thomaz Front Pharmacol Pharmacology The gastrointestinal and respiratory systems are colonized by a complex ecosystem of microorganisms called the microbiota. These microorganisms co-evolved over millions of years with the host, creating a symbiotic relationship that is fundamental for promoting host homeostasis by producing bioactive metabolites and antimicrobial molecules, and regulating the immune and inflammatory responses. Imbalance in the abundance, diversity, and function of the gut microbiota (known as dysbiosis) have been shown to increase host susceptibility to infections in the lungs, suggesting crosstalk between these organs. This crosstalk is now referred to as the gut-lung axis. Hence, the use of probiotics, prebiotics, and synbiotics for modulation of gut microbiota has been studied based on their effectiveness in reducing the duration and severity of respiratory tract infections, mainly owing to their effects on preventing pathogen colonization and modulating the immune system. This review discusses the role and responses of probiotics, prebiotics, and synbiotics in the gut-lung axis in the face of lung infections. Frontiers Media S.A. 2021-09-07 /pmc/articles/PMC8453009/ /pubmed/34557097 http://dx.doi.org/10.3389/fphar.2021.724033 Text en Copyright © 2021 Cruz, Ricci and Vieira. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Cruz, Clênio Silva Ricci, Mayra Fernanda Vieira, Angélica Thomaz Gut Microbiota Modulation as a Potential Target for the Treatment of Lung Infections |
title | Gut Microbiota Modulation as a Potential Target for the Treatment of Lung Infections |
title_full | Gut Microbiota Modulation as a Potential Target for the Treatment of Lung Infections |
title_fullStr | Gut Microbiota Modulation as a Potential Target for the Treatment of Lung Infections |
title_full_unstemmed | Gut Microbiota Modulation as a Potential Target for the Treatment of Lung Infections |
title_short | Gut Microbiota Modulation as a Potential Target for the Treatment of Lung Infections |
title_sort | gut microbiota modulation as a potential target for the treatment of lung infections |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453009/ https://www.ncbi.nlm.nih.gov/pubmed/34557097 http://dx.doi.org/10.3389/fphar.2021.724033 |
work_keys_str_mv | AT cruzcleniosilva gutmicrobiotamodulationasapotentialtargetforthetreatmentoflunginfections AT riccimayrafernanda gutmicrobiotamodulationasapotentialtargetforthetreatmentoflunginfections AT vieiraangelicathomaz gutmicrobiotamodulationasapotentialtargetforthetreatmentoflunginfections |